about
Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.Impaired oxidation of debrisoquine in patients with perhexiline neuropathyAntipyrine kinetics in liver disease and liver transplantation.Review article: prescribing medications in patients with cirrhosis - a practical guide.Conjugation pathways in liver disease.Propranolol disposition in patients with hepatosplenic schistosomiasis.The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation.Effects of cirrhosis on kinetics of aztreonam.Principles of pharmacotherapy: I. Pharmacodynamics.Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Disease states and drug pharmacokinetics.Clinical pharmacology. Elimination of drugs.Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis.Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis.Food, drugs, and bioavailability.An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease.Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.Intravenous lidocaine overdosage in a child.
P2860
Q24542426-AADDCDB5-40F9-4D6C-B33B-A598805039C8Q28366143-3847E6F4-86A7-4FE4-8C9A-D3CBCCEAB357Q34198161-AD54F603-7340-4175-9E49-06428C46F534Q34342554-272E68B8-35B9-4AC4-8315-27A2EE48E8DBQ34357251-9F2530DE-C040-45AF-AAB8-70CC824D2C5EQ34416863-E440B1DF-4678-43EC-8FE8-F80F0C19EBF4Q34447202-B66DAA43-6750-49D3-980B-71A64E279EB1Q35087638-2F482EFF-04C2-4D6C-9120-EE5BCB8E6917Q35639991-AB20D022-9400-43A1-AAC4-D8FED97961E2Q36313287-F7601187-4D10-4EA2-BACC-9DE2E8F8E0E9Q37337092-EA400682-EBB5-4C32-8C15-D6444EB9FD24Q37984567-6D1E95BF-EB1E-4054-84F2-D6F99865DFD8Q38689435-1B5955FF-718C-45E7-8677-7C95C914BD3DQ41745793-0393E763-2F83-4435-9CB9-779A80BD3831Q41858171-B1C56CE2-A1CA-4196-B020-B1C50444745CQ41871086-A8122CBA-038A-4CE1-812F-8A3F61B44C95Q41976255-BA4ED189-74B8-45AD-8680-51408DE1DE3AQ42064238-ABC410D8-C4E8-461B-8206-02DEEAB4CB0FQ46141539-7A58032A-023C-45CF-99A1-CFDBEC8F02ADQ46338578-E33FB54D-FD3C-41FB-A576-FCDA376A551DQ51431498-083CBBF2-1C22-44DC-B4CA-7579CAEEB6C2Q51816270-0D668899-F6BB-4465-B796-F839E8DF577F
P2860
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
1980年论文
@zh
1980年论文
@zh-cn
name
Hepatic disease and drug pharmacokinetics.
@en
type
label
Hepatic disease and drug pharmacokinetics.
@en
prefLabel
Hepatic disease and drug pharmacokinetics.
@en
P1476
Hepatic disease and drug pharmacokinetics.
@en
P2093
Mamelok RD
Williams RL
P304
P356
10.2165/00003088-198005060-00002
P577
1980-11-01T00:00:00Z
P6179
1018589200